Sara Ramella

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5163674/publications.pdf

Version: 2024-02-01

108	2,976	23	51
papers	citations	h-index	g-index
109	109	109	3733
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Stereotactic Radiation and Dual Human Epidermal Growth Factor Receptor 2 Blockade with Trastuzumab and Pertuzumab in the Treatment of Breast Cancer Brain Metastases: A Single Institution Series. Cancers, 2022, 14, 303.	1.7	4
2	The COVID-19 Status of Patients Is an Essential Determinant for Decision-Making by Radiation Oncologists: A European Survey. Cureus, 2022, 14, e22842.	0.2	2
3	Postoperative radiotherapy (PORT) in NSCLC: The end of a love? It is never too good to trust what appears. Lung Cancer, 2022, , .	0.9	O
4	Radiotherapy for HER 2 Positive Brain Metastases: Urgent Need for a Paradigm Shift. Cancers, 2022, 14, 1514.	1.7	5
5	Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era. Critical Reviews in Oncology/Hematology, 2022, 174, 103684.	2.0	2
6	The psychological impact of the covid-19 pandemic on radiotherapy cancer patients. Translational Oncology, 2022, 22, 101457.	1.7	4
7	Special Issue "Hepatobiliary and Pancreatic Cancers: Novel Strategies for of Diagnosis and Treatments― Journal of Clinical Medicine, 2022, 11, 3849.	1.0	1
8	Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in clinical routine. Radiotherapy and Oncology, 2021, 154, 269-273.	0.3	11
9	Long-Term Results of a Prospective Phase 2 Study on Volume De-Escalation in Neoadjuvant Chemoradiotherapy of Rectal Cancer. Practical Radiation Oncology, 2021, 11, e186-e194.	1.1	2
10	Radiation-Induced Pneumonitis in the Era of the COVID-19 Pandemic: Artificial Intelligence for Differential Diagnosis. Cancers, 2021, 13, 1960.	1.7	7
11	CA19.9 Serum Level Predicts Lymph-Nodes Status in Resectable Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis. Frontiers in Oncology, 2021, 11, 690580.	1.3	17
12	Sequential chemo-hypofractionated RT versus concurrent standard CRT for locally advanced NSCLC: GRADE recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Radiologia Medica, 2021, 126, 1117-1128.	4.7	18
13	Different Biliary Microbial Flora Influence Type of Complications after Pancreaticoduodenectomy: A Single Center Retrospective Analysis. Journal of Clinical Medicine, 2021, 10, 2180.	1.0	12
14	Exploring Deep Pathomics in Lung Cancer. , 2021, , .		2
15	Resilience in Radiotherapy Services During the COVID-19 Emergency: Collaboration Between the Regional Radiation Oncology Departments of Lazio, Abruzzo and Molise. Anticancer Research, 2021, 41, 3561-3565.	0.5	O
16	Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2021, 39, 2574-2585.	0.8	27
17	Role of Postoperative Radiotherapy in the Management for Resected NSCLC – Decision Criteria in Clinical Routine Pre- and Post-LungART. Clinical Lung Cancer, 2021, 22, 579-586.	1.1	9
18	Deep Reinforcement Learning for Fractionated Radiotherapy in Non-Small Cell Lung Carcinoma. Artificial Intelligence in Medicine, 2021, 119, 102137.	3.8	8

#	Article	IF	CITATIONS
19	Evaluating GANs in Medical Imaging. Lecture Notes in Computer Science, 2021, , 112-121.	1.0	5
20	The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of) Tj ETQq0 0 0 rgBT /C 2021, 38, 527-537.	Overlock 1	0 Tf 50 702 Td
21	Factors Predicting Pathological Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer: The Experience of a Single Institution with 269 Patients (STONE-01). Cancers, 2021, 13, 6074.	1.7	2
22	Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings. Radiologia Medica, 2020, 125, 214-219.	4.7	10
23	Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical) Tj ETQq $1\ 1\ 0$.	.784314 rş	gBT ₃ /Overlock
24	The role of postoperative thoracic radiotherapy and prophylactic cranial irradiation in early stage small cell lung cancer: Patient selection among ESTRO experts. Radiotherapy and Oncology, 2020, 145, 45-48.	0.3	9
25	A Bio-Imaging Signature as a Predictor of Clinical Outcomes in Locally Advanced Pancreatic Cancer. Cancers, 2020, 12, 2016.	1.7	6
26	Radiomics-Based Prediction of Overall Survival in Lung Cancer Using Different Volumes-Of-Interest. Applied Sciences (Switzerland), 2020, 10, 6425.	1.3	12
27	Radiotherapy for pain relief from bone metastases during Coronavirus (COVIDâ€19) pandemic. European Journal of Pain, 2020, 24, 1211-1212.	1.4	6
28	18F-choline PET/CT driven salvage radiotherapy in prostate cancer patients: up-date analysis with 5-year median follow-up. Radiologia Medica, 2020, 125, 668-673.	4.7	6
29	Proton beam or photon beam radiotherapy in the treatment of non-small-cell lung cancer. Lancet Oncology, The, 2020, 21, 873-875.	5.1	8
30	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. International Journal of Radiation Oncology Biology Physics, 2020, 107, 631-640.	0.4	40
31	ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer. Radiotherapy and Oncology, 2020, 152, 89-95.	0.3	23
32	Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. Critical Reviews in Oncology/Hematology, 2020, 148, 102862.	2.0	26
33	Can we prevent COVID-19 from causing victims among uninfected cancer patients?. Radiotherapy and Oncology, 2020, 149, 63.	0.3	1
34	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Radiotherapy and Oncology, 2020, 146, 223-229.	0.3	168
35	Repeated courses of radiation treatment in an HER2â€positive breast cancer patient with diffuse brain metastases: A case report. Breast Journal, 2020, 26, 1370-1371.	0.4	1
36	Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. Radiotherapy and Oncology, 2020, 149, 84-88.	0.3	13

#	Article	IF	CITATIONS
37	COVID-19 and radiation induced pneumonitis: Overlapping clinical features of different diseases. Radiotherapy and Oncology, 2020, 148, 201-202.	0.3	15
38	Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer – Decision criteria in routine practise. Radiotherapy and Oncology, 2020, 150, 26-29.	0.3	13
39	Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report. Journal of Thoracic Oncology, 2019, 14, 2109-2119.	0.5	189
40	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiotherapy and Oncology, 2019, 133, 163-166.	0.3	24
41	Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: Preliminary assessment of toxicity. Breast, 2019, 46, 70-74.	0.9	49
42	Prophylactic cranial irradiation in non-small cell lung cancer: the debate is open. Journal of Thoracic Disease, 2019, 11, S337-S340.	0.6	1
43	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiotherapy and Oncology, 2019, 135, 74-77.	0.3	14
44	Histologic transformation to small-cell lung cancer following gefitinib and radiotherapy in a patient with pulmonary adenocarcinoma. Tumori, 2019, 105, NP12-NP16.	0.6	9
45	Lung Cancer in Italy. Journal of Thoracic Oncology, 2019, 14, 2046-2052.	0.5	12
46	Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian) Tj ETQq0 0 Reviews in Oncology/Hematology, 2019, 134, 104-119.	0 rgBT /Ov 2.0	verlock 10 Tf . 10
47	Hypofractionated radiotherapy with concomitant boost for breast cancer: a dose escalation study. British Journal of Radiology, 2019, 92, 20180169.	1.0	5
48	Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian) Tj ETQq0 0 0 Reviews in Oncology/Hematology, 2019, 134, 87-103.) rgBT /Ov 2.0	erlock 10 Tf 5 7
49	ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiotherapy and Oncology, 2018, 127, 1-5.	0.3	141
50	Radiotherapy and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors in Renal Cancer. Chemotherapy, 2018, 63, 83-89.	0.8	7
51	Efficacy of a Propolis-Based Syrup (FARINGEL) in Preventing Radiation-Induced Esophagitis in Locally Advanced Lung Cancer. Chemotherapy, 2018, 63, 76-82.	0.8	8
52	Pacific trial: a new ocean or an abnormal wave?. Journal of Thoracic Disease, 2018, 10, 1225-1226.	0.6	1
53	A radiomic approach for adaptive radiotherapy in non-small cell lung cancer patients. PLoS ONE, 2018, 13, e0207455.	1.1	48
54	Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). Cancer Treatment Reviews, 2018, 71, 76-87.	3.4	38

#	Article	IF	Citations
55	Are We Ready for Histology-Driven Stereotactic Ablative Radiotherapy?. Journal of Thoracic Oncology, 2018, 13, 1441-1442.	0.5	4
56	Implementation of a voluntary deep inspiration breath hold technique (vDIBH) using BrainLab ExacTrac infrared optical tracking system. PLoS ONE, 2018, 13, e0195506.	1.1	5
57	Exploratory Radiomics for Predicting Adaptive Radiotherapy in Non-Small Cell Lung Cancer., 2018,,.		6
58	Local Control and Toxicity of Adaptive Radiotherapy Using Weekly CT Imaging: Results from the LARTIA Trial in Stage III NSCLC. Journal of Thoracic Oncology, 2017, 12, 1122-1130.	0.5	48
59	OA24.02 Locally Advanced Non-Small Cell Lung Cancer: RadioTherapy with Adaptive Strategy (LARTIA) Tj ETQq1 1	0.784314 0.5	1 4 rgBT /Over
60	Phase II study of induction chemotherapy followed by chemoradiotherapy in patients with borderline resectable and unresectable locally advanced pancreatic cancer. Scientific Reports, 2017, 7, 45845.	1.6	21
61	From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?. Expert Review of Anticancer Therapy, 2017, 17, 157-165.	1.1	0
62	Tumor epithelial tumors: do we expect a brighter or a grey future?. Journal of Thoracic Disease, 2017, 9, 4180-4181.	0.6	0
63	Radio(chemo)therapy in locally advanced nonsmall cell lung cancer. European Respiratory Review, 2016, 25, 65-70.	3.0	24
64	Thoracic oncology HERMES: European curriculum recommendations for training in thoracic oncology. Breathe, 2016, 12, 249-255.	0.6	18
65	A new three-dimensional conformal radiotherapy (3DCRT) technique for large breast and/or high body mass index patients: evaluation of a novel fields assessment aimed to reduce extra–target-tissue irradiation. British Journal of Radiology, 2016, 89, 20160039.	1.0	4
66	Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 94, 612-620.	0.4	49
67	A cast of shadow on adjuvant radiotherapy for prostate cancer: A critical review based on a methodological perspective. Critical Reviews in Oncology/Hematology, 2016, 97, 322-327.	2.0	12
68	Estimation of patient setup uncertainty using BrainLAB Exatrac Xâ€Ray 6D system in imageâ€guided radiotherapy. Journal of Applied Clinical Medical Physics, 2015, 16, 99-107.	0.8	26
69	Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer. Radiation Oncology, 2015, 10, 255.	1.2	10
70	Breakthrough Pain Management in Patients Undergoing Radiotherapy: A National Survey on Behalf of the Palliative and Supportive Care Study Group. Tumori, 2015, 101, 603-608.	0.6	6
71	In Reply to Zilli and Miralbell. International Journal of Radiation Oncology Biology Physics, 2015, 91, 682.	0.4	1
72	SBRT: A viable option for treating adrenal gland metastases. Reports of Practical Oncology and Radiotherapy, 2015, 20, 484-490.	0.3	36

#	Article	IF	CITATIONS
73	The first survey on defensive medicine in radiation oncology. Radiologia Medica, 2015, 120, 421-429.	4.7	25
74	Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non–Small-Cell Lung Cancer Beneficial? A Multi-Institutional Propensity Score MatchedÂAnalysis. International Journal of Radiation Oncology Biology Physics, 2015, 91, 133-139.	0.4	17
75	A Clinical Score, Including Biohumoral Parameters, Is a Useful Pretest Index to Discriminate Pulmonary Infections from Radiation Damage in Chemoradiation-Treated Lung Cancer Patients. Cancer Investigation, 2014, 32, 110-114.	0.6	4
76	Fractionated stereotactic radiosurgery for patients with brain metastases. Journal of Neuro-Oncology, 2014, 117, 295-301.	1.4	147
77	18F-Choline Positron Emission Tomography/Computed Tomography–Driven High-Dose Salvage Radiation Therapy in Patients With Biochemical Progression After Radical Prostatectomy: Feasibility Study in 60 Patients. International Journal of Radiation Oncology Biology Physics, 2014, 90, 296-302.	0.4	26
78	Initial experience of ArcCHECK and 3DVH software for RapidArc treatment plan verification. Medical Dosimetry, 2014, 39, 276-281.	0.4	18
79	Predicting Esophagitis After Chemoradiation Therapy for Non-Small Cell Lung Cancer: An Individual Patient Data Meta-Analysis. International Journal of Radiation Oncology Biology Physics, 2013, 87, 690-696.	0.4	157
80	Predicting Radiation Pneumonitis After Chemoradiation Therapy for Lung Cancer: An International Individual Patient Data Meta-analysis. International Journal of Radiation Oncology Biology Physics, 2013, 85, 444-450.	0.4	545
81	Erlotinib and Concurrent Chemoradiation in Pretreated NSCLC Patients: Radiobiological Basis and Clinical Results. BioMed Research International, 2013, 2013, 1-5.	0.9	12
82	The Role of Mammography after Breast-Conserving Surgery and Adjuvant Chemotherapy. Tumori, 2013, 99, 199-203.	0.6	2
83	Radiotherapy in palliative treatment of metastatic NSCLC: not all one and the same. Annals of Palliative Medicine, 2013, 2, 92-4.	0.5	3
84	Radiotherapy in Italy for Non-Small Cell Lung Cancer: Patterns of Care Survey. Tumori, 2012, 98, 66-78.	0.6	19
85	MR imaging of rectal cancer before and after chemoradiation therapy. Radiologia Medica, 2012, 117, 1125-1138.	4.7	21
86	Whole-breast irradiation: a subgroup analysis of criteria to stratify for prone position treatment. Medical Dosimetry, 2012, 37, 186-191.	0.4	18
87	Radiotherapy in Italy for non-small cell lung cancer: patterns of care survey. Tumori, 2012, 98, 66-78.	0.6	8
88	Beams Arrangement in Non-Small Cell Lung Cancer (NSCLC) According to PTV and Dosimetric Parameters Predictive of Pneumonitis. Medical Dosimetry, 2010, 35, 169-178.	0.4	6
89	Adding Ipsilateral V20 and V30 to Conventional Dosimetric Constraints Predicts Radiation Pneumonitis in Stage IIIA–B NSCLC Treated With Combined-Modality Therapy. International Journal of Radiation Oncology Biology Physics, 2010, 76, 110-115.	0.4	74
90	Parathyroid Hormone-Related Peptide and Parathyroid Hormone-Related Peptide Receptor Type 1 Expression in Human Lung Adenocarcinoma. Chest, 2010, 137, 898-908.	0.4	12

#	Article	IF	Citations
91	Integration between <i>in vivo</i> dosimetry and image guided radiotherapy for lung tumors. Medical Physics, 2009, 36, 2206-2214.	1.6	24
92	Design and evaluation of a methodology to perform personalized visual biofeedback for reducing respiratory amplitude in radiation treatment. Medical Physics, 2009, 36, 1467-1472.	1.6	16
93	In patient dose reconstruction using a cine acquisition for dynamic arc radiation therapy. Medical and Biological Engineering and Computing, 2009, 47, 425-433.	1.6	12
94	Multimodality Treatment of Stage III Non-small Cell Lung Cancer: Analysis of a Phase II Trial Using Preoperative Cisplatin and Gemcitabine with Concurrent Radiotherapy. Journal of Thoracic Oncology, 2009, 4, 1517-1523.	0.5	24
95	Use of the Semiconductor Nanotechnologies & Discovery, 2009, 4, 207-215.	0.8	6
96	Novel Prognostic Groups in Thymic Epithelial Tumors: Assessment of Risk and Therapeutic Strategy Selection. International Journal of Radiation Oncology Biology Physics, 2008, 71, 420-427.	0.4	21
97	Dynamic conformal arc therapy: Transmitted signal <i>in vivo</i> dosimetry. Medical Physics, 2008, 35, 1830-1839.	1.6	10
98	Application of a practical method for the isocenter point <i>in vivo</i> dosimetry by a transit signal. Physics in Medicine and Biology, 2007, 52, 5101-5117.	1.6	45
99	Multimodality treatment of unresectable stage III non–small cell lung cancer: Interim analysis of a phase II trial with preoperative gemcitabine and concurrent radiotherapy. Journal of Thoracic and Cardiovascular Surgery, 2006, 131, 314-321.e3.	0.4	16
100	Dose and volume as predictive factors of pulmonary toxicity. Rays, 2005, 30, 175-80.	0.2	1
101	Role of induction therapy in esophageal cancer. Rays, 2005, 30, 329-33.	0.2	3
102	Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA–IIIB) non-small-cell lung cancer: long-term results according to downstaging. Annals of Oncology, 2004, 15, 389-398.	0.6	56
103	Assessing the value of neoadjuvant chemoradiotherapy and pathologic downstaging in the treatment of non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2004, 128, 489-490.	0.4	4
104	Dose fractionation and biological optimization in lung cancer. Rays, 2004, 29, 319-26.	0.2	1
105	Lymphatic drainage, CTV and molecular imaging in non-small cell lung cancer. Rays, 2003, 28, 299-302.	0.2	2
106	Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase III randomized trial. Radiotherapy and Oncology, 2002, 62, 11-19.	0.3	167
107	Incidental surgical findings of a phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with unresectable non-small cell lung cancer. Lung Cancer, 2002, 37, 207-212.	0.9	10
108	Phase I Trial of Weekly Gemcitabine and Concurrent Radiotherapy in Patients With Inoperable Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2002, 20, 804-810.	0.8	63